E Fund Management Co. Ltd. Makes New Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

E Fund Management Co. Ltd. acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 12,236 shares of the company’s stock, valued at approximately $235,000.

A number of other institutional investors have also recently made changes to their positions in the business. R Squared Ltd purchased a new stake in Viridian Therapeutics during the 4th quarter worth approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after buying an additional 2,036 shares during the period. Arizona State Retirement System grew its holdings in shares of Viridian Therapeutics by 19.5% during the fourth quarter. Arizona State Retirement System now owns 16,596 shares of the company’s stock valued at $318,000 after buying an additional 2,708 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Viridian Therapeutics by 3.3% in the 4th quarter. Principal Financial Group Inc. now owns 178,444 shares of the company’s stock valued at $3,421,000 after acquiring an additional 5,634 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Viridian Therapeutics in the 3rd quarter worth $149,000.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, Royal Bank of Canada increased their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Stock Up 0.4 %

VRDN opened at $15.94 on Monday. The company has a fifty day moving average of $17.79 and a two-hundred day moving average of $19.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.70 and a beta of 1.05.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. On average, research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.